F. Danhier

Biomaterials · 2009–2017

A researcher in the Science corpus: 6 papers; trusts 13 researchers and is trusted by 4 researchers here, as inferred from the citation graph.

Subfields

• Biomaterials — 82 citations into it; #534 of 2,152 by trust here, #742 by citations
• Molecular Biology — 66 citations into it; #6,074 of 17,773 by trust here, #5,968 by citations
• Biomedical Engineering — 44 citations into it; #3,189 of 10,734 by trust here, #3,931 by citations
• Oncology — 23 citations into it
• Materials Chemistry — 17 citations into it
• Immunology — 13 citations into it
• Cancer Research — 12 citations into it
• Immunology and Allergy — 7 citations into it

Whom F. Danhier trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Peter Carmeliet
2. Rakesh K. Jain
3. R. Duncan
4. H. Hillaireau
5. H. Maeda
6. D. Cheresh
7. L. Brannon-Peppas
8. P. Couvreur
9. O. Farokhzad
10. Y. Barenholz

Who trusts F. Danhier overall

1. Jun Wu
2. Pranali P. Deshpande
3. S. Hua
4. C. Roma-Rodrigues
5. Vladimir Torchilin
6. S. Biswas
7. Upendra Bulbake
8. R. Mendes

Papers from F. Danhier's perspective

Ordered by how strongly the researchers F. Danhier trusts endorse each paper. Same corpus, a different order for every researcher.

1. Molecular mechanisms and clinical applications of angiogenesis (Nature)
2. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. (Journal of Clinical Oncology)
3. Ligand-targeted therapeutics in anticancer therapy (Nature Reviews. Cancer)
4. Nanoparticles for drug delivery in cancer treatment. (Urologic oncology)
5. Active targeting schemes for nanoparticle systems in cancer therapeutics. (Advanced Drug Delivery Reviews)
6. Strategies in the design of nanoparticles for therapeutic applications (Nature reviews. Drug discovery)
7. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. (Journal of the National Cancer Institute)
8. Impact of nanotechnology on drug delivery. (ACS Nano)
9. Nanoparticles in cancer therapy and diagnosis. (Advanced Drug Delivery Reviews)
10. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. (Journal of Clinical Oncology)

Their papers

• To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. (2010) — 2,572 citations
• To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine? (2016) — 1,080 citations
• Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. (2009) — 608 citations
• PLGA-based nanoparticles: an overview of biomedical applications. (2012) — 3,515 citations
• RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. (2012) — 898 citations
• Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures (2017) — 315 citations